CollPlant Biotechnologies Ltd - Ordinary Shares New

NASDAQ:CLGN  
8.21
+0.01 (+0.12%)
6:31:44 PM EDT: $7.76 -0.45 (-5.48%)
Products, Strategic Combinations, Regulatory

Collplant, Tel Aviv University And Sheba Medical Center To Co-Develop 3D Bioprinted Human Intestine Model For Drug Discovery

Published: 11/15/2022 12:42 GMT
CollPlant Biotechnologies Ltd - Ordinary Shares New (CLGN) - Collplant, Tel Aviv University and Sheba Medical Center Join Forces to Co-develop Rhcollagen-based 3d Bioprinted Human Intestine Model for Drug Discovery and Personalized Treatment of Ulcerative Colitis.
Collplant Biotechnologies - Co to Fund Development and Receive Exclusive License to Manufacture and Commercialize Human Intestine Tissue Model.